Patients with Ewing’s sarcoma should be transferred to a comprehensive cancer center for evaluation and management when the diagnosis is suspected. Proper biopsy technique is essential to preserve all therapeutic options, including limb preservation surgery. In addition to conventional histologic examination, biopsy tissue must be obtained for molecular biology studies. Demonstration of the consistent chromosomal translocation associated with Ewing’s sarcoma is essential for diagnosis, and the specific type of fusion transcript has prognostic implications. Treatment must be intimately coordinated among oncologist, surgeon, and radiation oncologist. Successful treatment requires systemic, multi-agent chemotherapy and local control. The primary tumor can be treated with surgery, radiation therapy, or a combination of the two. The choice of modality should be dictated by the age of the patient, location of the primary tumor, functional consequences of the intervention, and concern about late effects, especially secondary malignancy. Treatment of the patient who presents with clinically detectable metastatic disease or who relapses after initial therapy remains unsatisfactory and controversial.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Delattre O, Zucman J, Melot T, et al.: The Ewing family of tumors—a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994, 331:294–299. This study covers delineation of the unique chromosomal translocation and specific fusion transcripts associated with Ewing’s sarcoma. The identification of these transcripts led to improved precision in diagnosis, greater sensitivity for detection of minimal or residual disease, and key clues to the pathogenesis of Ewing’s sarcoma.PubMedCrossRefGoogle Scholar
- 2.Horowitz ME, Malawar MM, Soo SY, Hicks MJ: Ewing’s sarcoma family of tumors: Ewing’s sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In Principles and Practice of Pediatric Oncology, edn 3. Edited by Pizzo and Poplack. Philadelphia: Lippincott Williams & Wilkins; 1997:844–845.Google Scholar
- 6.Grier H, Krailo M, Link M, et al.: Improved outcome in nonmetastatic Ewing’s sarcoma (EWS) and PNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), Adriamycin (Ad), cyclophosphamide (C), and actinomycin (A): a Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) report. Proc Am Soc Clin Oncol 1994, 13:A1443. The addition of ifosfamide and etoposide to cyclophosphamide, doxorubicin, and vincristine significantly improves the probability for event-free survival in Ewing’s sarcoma.Google Scholar
- 7.Miser JS, Krailo M, Meyers P, et al.: Metastatic Ewing’s sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone; failure of new regimens to improve outcome. Proc Am Soc Clin Oncol 1996, 15:A1472.Google Scholar
- 14.Wunder JS, Paulian G, Huvos AG, et al.: The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998, 80:1020–1033. Patients with Ewing’s sarcoma typically receive induction chemotherapy. When they undergo surgery for definitive local control, the degree of necrosis in the primary tumor correlates with the subsequent probability for event-free survival.PubMedCrossRefGoogle Scholar
- 16.Meyers P, Nachman J, Krailo M, et al.: Induction chemotherapy followed by melphalan/etoposide/total body irradiation and peripheral blood stem cell support for patients with newly diagnosed high-risk Ewing’s sarcoma. Proc Am Soc Clin Oncol 2000, 19:A2287. Consolidation with high-dose therapy with melphalan, etoposide, and total body irradiation followed by autologous stem cell reconstitution does not improve the prognosis for patients with very high-risk Ewing’s sarcoma.Google Scholar
- 17.Hartmann O, Pinkerton R, Dallorso G, et al.: A multivariate and matched pair analysis on high-risk Ewing Tumor (ET) patients treated by megatherapy (MGT) and stem cell reinfusion in Europe. Proc Am Soc Clin Oncol 1999, 18:A2144.Google Scholar
- 19.Goletz TJ, Zhan S, Pendleton CD, et al.: Cytotoxic T cell responses against the EWS/FLI-1 Ewing’s sarcoma fusion protein and the PAX3/FKHR alveolar rhabdomyosarcoma fusion protein. Proc Annu Meet Am Assoc Cancer Res 1996, 37:A3243.Google Scholar